Behavioral validation of avolition in schizophrenia

Schizophrenia Research

Volumn 138, Issue 2-3, 2012, Pages 255-261

  Trémeau, Fabien ^a,b,c   Nolan, Karen A ^a,b   Malaspina, Dolores ^b   Javitt, Daniel C ^a,d  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Rockland Psychiatric Center   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Avolition; Direct observation; MASS; Negative symptoms; PANSS; SANS; Schizophrenia; Time sampling

Indexed keywords

ADULT; AGED; ARTICLE; AVOLITION; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MOTIVATION; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; SCHIZOPHRENIA; SELF EVALUATION; SELF REPORT; SOCIAL INTERACTION; SOCIAL PARTICIPATION;

ADULT; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; MOTIVATION; OBSERVATION; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF-ASSESSMENT;

EID: 84862152056     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.02.018     Document Type: Article

References (37)

1. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 1992, 6:201-208.
2. Alphs L.D., Summerfelt A., Lann H., Muller R.J. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol. Bull. 1989, 25:159-163.
3. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 1989, 49-58.
4. Atkinson M., Zibin S., Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am. J. Psychiatry 1997, 154:99-105.
5. Barch D.M. The relationships among cognition, motivation, and emotion in schizophrenia: how much and how little we know. Schizophr. Bull. 2005, 31:875-881.
6. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
7. Blanchard J.J., Kring A.M., Horan W.P., Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr. Bull. 2011, 37:291-299.
8. Bowie C.R., Twamley E.W., Anderson H., Halpern B., Patterson T.L., Harvey P.D. Self-assessment of functional status in schizophrenia. J. Psychiatr. Res. 2007, 41:1012-1018.
9. Bromley E., Mikesell L., Mates A., Smith M., Brekke J.S. A video ethnography approach to assessing the ecological validity of neurocognitive and functional measures in severe mental illness: results from a feasibility study. Schizophr. Bull. 2011, doi:10.1093/schbul/sbr002 (Electronic publication ahead of print).
10. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164:1593-1602.
11. Castner S.A., Goldman-Rakic P.S. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 1999, 20:10-28.
12. First M.B., Spizer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0, 8/98 revision) 1998, Biometrics Research Department, New York State Psychiatric Institute.
13. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36:359-369.
14. Foussias G., Mann S., Zakzanis K.K., van Reekum R., Remington G. Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophr. Res. 2009, 115:333-337.
15. Guy W. ECDEU. Assessment Manual for Psychopharmacology 1976, 218-222. US Department of Health and Human Services (ADM), Rockville, MD. W. Guy (Ed.).
16. Harvey P.D., Velligan D.I., Bellack A.S. Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr. Bull. 2007, 33:1138-1148.
17. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
18. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
19. Kiang M., Christensen B.K., Remington G., Kapur S. Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophr. Res. 2003, 63:79-88.
20. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989, 30:119-123.
21. Kraepelin E. Psychiatry: A Textbook for Students and Physicians 1990, Science History Publications/U.S.A., Canton, MA.
22. Linn G.S., O'Keeffe R.T., Lifshitz K., Schroeder C., Javitt D.C. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology (Berl) 2007, 192:27-38.
23. Marin R.S., Biedrzycki R.C., Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991, 38:143-162.
24. McClelland D.C., Koestner R., Weinberger J. How do self-attributed and implicit motives differ?. Psychol. Rev. 1989, 96:690-702.
25. Messinger J.W., Trémeau F., Antonius D., Mendelsohn E., Prudent V., Stanford A.D., Malaspina D. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin. Psychol. Rev. 2011, 31:161-168.
26. Nakagami E., Xie B., Hoe M., Brekke J.S. Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr. Res. 2008, 105:95-104.
27. Nived O., Sturfelt G., Eckernas S.A., Singer P. A comparison of 6 months' compliance of patients with rheumatoid arthritis treated with tenoxicam and naproxen. Use of patient computer data to assess response to treatment. J. Rheumatol. 1994, 21:1537-1541.
28. Nolan K.A., Citrome L. Reducing inpatient aggression: does paying attention pay off?. Psychiatr. Q. 2008, 79:91-95.
29. Nopoulos P., Miller M., Flaum M., Andreasen N.C. Issues in the assessment of negative symptom treatment response. Assessment of Negative Symptom Treatment Response 2001, 19-32. AJP Press. R. Keefe, J. McEvoy (Eds.).
30. Perry W., Minassian A., Paulus M.P., Young J.W., Kincaid M.J., Ferguson E.J., Henry B.L., Zhuang X., Masten V.L., Sharp R.F., Geyer M.A. A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch. Gen. Psychiatry 2009, 66:1072-1080.
31. Sabbag S., Twamley E.M., Vella L., Heaton R.K., Patterson T.L., Harvey P.D. Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophr. Res. 2011, 131:250-255.
32. Sayers S.L., Curran P.J., Mueser K.T. Factor structure and construct validity of the Scale for the Assessment of Negative Symptoms. Psychol. Assess. 1996, 8:269-280.
33. Schelde T. Ethological research in psychiatry. Ethol. Sociobiol. 1994, 15:349-368.
34. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
35. Steiger J.H. Tests for comparing elements of a correlation matrix. Psychol. Bull. 1980, 87:245-251.
36. Trémeau F., Goggin M., Antonius D., Czobor P., Hill V., Citrome L. A new rating scale for negative symptoms: the Motor-Affective-Social Scale. Psychiatry Res. 2008, 160:346-355.
37. Ward R.D., Simpson E.H., Kandel E.R., Balsam P.D. Modeling motivational deficits in mouse models of schizophrenia: behavior analysis as a guide for neuroscience. Behav. Processes 2011, 87:149-156.